

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Manpreet S. Wadhwa, et al

:

EXAMINER: Fozia M. Hamud

SERIAL NO.: **10/583,923**

:

ART UNIT: 1647

FILED: **May 14, 2007**

:

CONF. NO.: 4848

FOR: **Stable Growth Hormone Liquid Formulation**

:

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicants, copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

The Commissioner is hereby authorized to charge the sum of \$180.00 to Deposit Account No. 16-1445 to cover the cost of this submission in accordance with 37 CFR 1.97(c) and 1.17(p). The Commissioner is further authorized to charge any additional fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment, to Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: 29 February 2012

/John A. Wichtowski/
John A. Wichtowski
Attorney for Applicant(s)
Reg. No. 48,032

Pfizer Inc.
Patent Department, MS 8260-2141
Eastern Point Road
Groton, CT 06340
(860) 715-6645